Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million. San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes. Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem […]
ViaCyte
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients […]
Gore adds $10m to ViaCyte investment
W.L. Gore put up a $10 million convertible note for ViaCyte and the Type I diabetes treatment they’re working on. Last year the companies inked a deal to work on the synthetic pancreas ViaCyte is developing. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the […]
ViaCyte launches cell replacement trial for Type I diabetes
Regenerative medicine company ViaCyte said today that the first patients have been implanted in a trial of its islet cell replacement therapy, PEC-Direct. San Diego-based ViaCyte is developing the cell therapy as a functional cure for patients with Type I diabetes who are at risk of suffering acute life-threatening complications. The company’s open-label clinical trial […]
ViaCyte looks to cell replacement therapy to cure Type I diabetes
ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada. The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct […]
ViaCyte, Gore ink co-development deal for synthetic pancreas
ViaCyte and W.L. Gore & Assoc. said today that they inked a co-development deal for the synthetic pancreas ViaCyte is developing to treat diabetes. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the skin. The newly created pancreatic cells generate insulin and […]
